Methods for detecting glioblastoma in extracellular vesicles
AssigneeRegents of the University of Minnesota
InventorOkay SAYDAM
Life of this patent
Estimating the term…
Abstract
In certain embodiments, the present invention provides a panel of probes associated with glioblastoma that hybridize to nucleic acid and kits that comprise a collection of panels of probes associated with glioblastoma. In certain embodiments, the present invention provides a method of detecting the presence of biomarkers associated with an increased risk of glioblastoma in a human subject. In certain embodiments, the present invention provides a method of treating a human subject for glioblastoma.
Claims25
A panel of probes that hybridize to nucleic acid, the panel comprising
- (a) at least 2 probes specific for IDH1-wt or IDH1 R132H selected from the group consisting of AC108449.2, RNA5SP145, FP671120.11, AC016737.2, AC017104.4, RPS8P6, AC105339.6, BNC2-AS1, AC007040.1, AC091932.2, AL589986.1, PSMC1P10, AC009248.3, SOCAR, S100A11, PIGH, AL132708.1, LAGE3, AC020910.5, TOMM20L, AL049874.3, UNC93B7, CEBPD, and Z99496.1;
- (b) at least 2 probes specific for a p53 mutation selected from the group consisting of RNA5SP226, AL390728.3, CDRT7, RNA5SP145, AC108449.2, PNPP1, S100A7L2, AMZ2, AC026202.3, EEF1A1P26, LARGE-IT1, TOMM22P4, RASL11B, IGLV2-8, and AC008964.1;
- (c) at least 2 probes specific for MGMT promoter methylation selected from the group consisting of RNA5SP226, IGLV2-8, MTND6P33, AC108449.2, SHISA8, ARHGAP27P2, AL390728.3, PSMC1P10, AC017104.4, UNC93B7, AL732314.8, AL133346.1, PNPP1, AL132708.1, RNU1-2, RNA5SP145, and Z93930.3:
- or
- (d) at least 2 probes specific for TERT promoter mutation selected from the group consisting of BNC2-AS1, AC017104.4, AC009248.3, AC108449, AC007040.1, RNA5SP145, LAGE3, AC103834.1, UNC93B7, AC016737.2, PNPP1, MTND6P33, FP671120.11, FP700111.1, TOMM20L, AC021321.1, SOCAR, RN7SL8P, RNU1-2, and LARGE-IT1.
2-5. (canceled)
(canceled)
A method of detecting glioblastoma in a patient comprising:
- (a) obtaining a sample from the patient;
- (b) isolating extracellular vesicles from the sample;
- and
- (c) detecting expression of at least one cancer marker in the isolated extracellular vesicles.
Dependencies are inferred from the claim text.